Navigation Links
Syndax Pharmaceuticals Elects Arlene Morris to Board of Directors
Date:6/8/2011

WALTHAM, Mass., June 8, 2011 /PRNewswire/ -- Syndax Pharmaceuticals, a clinical-stage epigenetics oncology company, announced that Arlene Morris has been elected to the board of directors.  Ms. Morris most recently was the chief executive officer and a member of the board of directors of Affymax, Inc., a biopharmaceutical company that was spun out of GlaxoSmithKline (GSK) in 2001 to develop a pipeline of synthetic peptide-based drug candidates for the treatment of anemia in dialysis patients.  

"Arlene is bringing to Syndax extensive biotechnology and pharmaceutical experience in general management, marketing, sales, business development and strategic marketing," said Dennis Podlesak, chairman of the Syndax board of directors.  "With entinostat entering a phase 3 program this is a great time for Arlene to leverage her extensive experience and provide guidance as we are moving in to the final stages of clinical development."

"I am excited to join the board as Syndax moves into pivotal trials with entinostat in women with metastatic breast cancer, an area where resistance poses an ongoing problem," said Ms. Morris.  "Syndax provides a great opportunity for me to contribute to the direction of a company with a promising oncology pipeline aimed at improving survival outcomes with a non-chemotherapy option."

During her eight years as president and CEO at Affymax, Ms. Morris led the company through the development of peginesatide (Hematide™), a strategic collaboration with Takeda and an Initial Public Offering.  Prior to Affymax Ms. Morris was the president and CEO of Clearview Projects, an advisory firm which counsels biopharmaceutical and biotechnology companies on strategic transactions. Before that she was the senior vice president, business development at Coulter, a biotechnology company focused on immunotherapeutic approaches to cancer, autoimmune and infectious diseases, where she completed numerous transactio
'/>"/>

SOURCE Syndax Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Syndax Pharmaceuticals Entinostat Shows Clinical Promise in Patients with Advanced Hormone Refractory Breast Cancer
2. Syndax Pharmaceuticals to Present at Sachs Biotech in Europe Investor Forum
3. Syndax Pharmaceuticals Announces Issuance of UK Patent for Entinostat
4. Syndax Pharmaceuticals Entinostat Plus Erlotinib Improves Survival in Select NSCLC Patients
5. Syndax Pharmaceuticals Entinostat in Combination Shows Activity in Breast Cancer
6. Syndax Pharmaceuticals to Present at Biotech Showcase 2011
7. Syndax Announces Publication of Entinostat NSCLC Data in Cancer Research
8. Syndax Announces Start of NCI Sponsored Phase 2 Study of Entinostat in Combination in Triple Negative Breast Cancer
9. Syndax Pharmaceuticals Announces Entinostat Data at 102nd Annual American Association for Cancer Research Meeting
10. Syndax Pharmaceuticals Announces Issuance of US Patent for Entinostat
11. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... , Sept. 2, 2014 Particle Sciences, ... to its investment in development and manufacturing capabilities with ... Karl Mueller , Particle Sciences, Associate Director Clinical ... pace adding clean room square footage, equipment and staff ... clients.  The company now has over 6000ft 2 ...
(Date:9/2/2014)... Sept. 2, 2014 /PRNewswire-iReach/ -- Ortho Development® Corporation (ODEV) ... Stem, the latest addition to its growing hip ... intended for use in total hip arthroplasty and ... Alpine was developed based ... ODEV,s engineers worked closely with a select team ...
(Date:9/2/2014)... NEW YORK , September 2, 2014 ... regarding WellPoint Inc. (NYSE: WLP ), Tekmira ... (NYSE: ZTS ), Sanofi SA (NYSE: ... wealth members receive these notes ahead of publication. To ... http://www.analystsreview.com/6142-100free . , ,-- ,WellPoint Inc. Research Reports ,WellPoint ...
Breaking Medicine Technology:Particle Sciences Expands Drug Eluting Device Capabilities and Overall Clinical Trial Manufacturing Resources 2Ortho Development Receives FDA Clearance for Alpine Hip Stem 2Upcoming Event, Positive Findings, Regulatory Approvals, and Vaccine License - Research Reports on WellPoint, Tekmira, Zoetis, Sanofi and GSK 2Upcoming Event, Positive Findings, Regulatory Approvals, and Vaccine License - Research Reports on WellPoint, Tekmira, Zoetis, Sanofi and GSK 3Upcoming Event, Positive Findings, Regulatory Approvals, and Vaccine License - Research Reports on WellPoint, Tekmira, Zoetis, Sanofi and GSK 4Upcoming Event, Positive Findings, Regulatory Approvals, and Vaccine License - Research Reports on WellPoint, Tekmira, Zoetis, Sanofi and GSK 5Upcoming Event, Positive Findings, Regulatory Approvals, and Vaccine License - Research Reports on WellPoint, Tekmira, Zoetis, Sanofi and GSK 6
(Date:9/2/2014)... 2014 TCG, a leading government technology strategy ... one of the fastest-growing companies in America for the seventh ... was previously recognized in 2013, 2012, 2011, 2010, 2009, 2008, ... grown 86% from 2010 to 2013, ranking the company at ... in America - up 635 spots from 2013! More information ...
(Date:9/2/2014)... (PRWEB) September 02, 2014 The use ... blood thinners is growing at a rapid pace, even ... mount in courts around the U.S., Bernstein Liebhard LLP ... Journal of Medicine, within a year of its 2011 ... Xarelto as warfarin, a blood thinner that has been ...
(Date:9/2/2014)... News) -- Complications are rare among breast cancer ... study indicates. However, the researchers did find ... slightly higher risk for certain complications than a ... 18,000 breast cancer patients who had a single ... reconstruction and were followed for 30 days after ...
(Date:9/2/2014)... a large population-based study of randomly selected participants ... (MCI) occurred twice more often in individuals diagnosed ... association was only observed in middle-aged participants (50-65 ... association vanished. This study is published in the ... concept of MCI describes an intermediate state between ...
(Date:9/2/2014)... Medex Analytic Services is delighted ... in Coral Springs, Fla. due to their greater than ... objectives for the 2014 year by distinguishing Medex in ... requested a higher level of service and professionalism in ... and the industry has responded.” , The location of ...
Breaking Medicine News(10 mins):Health News:TCG One of the Fastest-Growing Companies in America – for the Eighth Time! 2Health News:Xarelto Lawsuit News: Bernstein Liebhard LLP Comments on Growing Use of Xarelto in Spite of Mounting Product Liability Litigation 2Health News:Xarelto Lawsuit News: Bernstein Liebhard LLP Comments on Growing Use of Xarelto in Spite of Mounting Product Liability Litigation 3Health News:Xarelto Lawsuit News: Bernstein Liebhard LLP Comments on Growing Use of Xarelto in Spite of Mounting Product Liability Litigation 4Health News:Complication Rates Low With Mastectomy, Breast Reconstruction: Study 2Health News:Diabetes mellitus and mild cognitive impairment: Higher risk in middle age? 2Health News:Medex Analytic Services Announces New Location for Corporate Headquarters 2
... known that diabetes, one of the world’s leading debilitating diseases, ... 194 million adults worldwide. Therefore, there is a huge demand ... the patients. ,There are two types of diabetes: ... for approximately 5% of all the cases. This type is ...
... been used by a pediatric research team to scrutinize ... small defects that lead to genetic diseases //. ... detect these abnormalities, the new research may lead to ... that lead to mental retardation. ,“For years, ...
... in Australia have been linked to the work place each ... //and the University of Sydney has shown that about 1,600 ... asbestos, passive smoking, fumes and exhaust at work. Several cases ... a work related origin. ,Professor Lin Fritschi, lead ...
... are planning to demand the government to levy heavy tax ... mainly combat the nation's obesity epidemic. The issue mainly addresses ... of salt added to burgers and processed foods. The ... to obesity. Due to this the sales of soft drinks ...
... CHICAGO - Abnormal glucose metabolism, which occurs when the ... twice as common among patients //with chronic nerve dysfunction ... may be a risk factor for the condition, according ... in the August 2006 print issue of Archives of ...
... have left its impact on the six million care givers in ... because of caring //. ,The survey revealed that only ... GP while 90% of them considered that they should be offered ... that their own health problems affected their ability to care. Besides ...
Cached Medicine News:Health News:Inhaled Insulin: A New Modality for Management of Diabetes 2Health News:Hunt for Chromosomal Errors Which Cause Genetic Diseases 2Health News:Hunt for Chromosomal Errors Which Cause Genetic Diseases 3Health News:Hunt for Chromosomal Errors Which Cause Genetic Diseases 4Health News:Work Related Cancer on the Rise in Australia 2Health News:Abnormal Glucose Metabolism May Contribute to Chronic Nerve Disorder 2Health News:Care Workers Need Some Care Too 2
Versatility of the DFS Standard Fixator provides unsurpassed below-the-ring correction of angular, rotational and translational deformities. Length discrepancy can be precisely corrected in 1/4mm inc...
The PreFix™ temporary fixator prepares you for any situation that requires rapid stabilization of complex fractures....
Angulation, translation and rotation. A whole different point of view. The Sheffield Ring Fixation System is a design achievement that advances the possibilities of fracture management....
For radial/ulnar translation, angulation, dorsal/volar translation, and incremental longitudinal distraction, this advanced system is appropriate when incremental adjustment provides an adjunctive me...
Medicine Products: